Bilateral ovarian serous cystadenocarcinoma metastasizing to cervix: a rare case report

Arati Mallick; Saubhagya K. Jena; Debasis Kuanar

doi:10.18203/2320-1770.ijrcog20184550

Authors

Arati Mallick Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, Sijua, Bhubaneswar, Odisha, India
Saubhagya K. Jena Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, Sijua, Bhubaneswar, Odisha, India
Debasis Kuanar Department of Anesthesiology, Care Hospital, Bhubaneswar, Odisha, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20184550

Keywords:

Cervical metastasis, Ovarian cancer, Ovarian serous cystadenocarcinoma, Secondary tumors in uterine cervix

Abstract

Ovarian carcinoma is the second most common gynaecologic cancer and the leading cause of death from gynaecologic malignancy. Two-third of all malignant epithelial ovarian tumors are constituted by serous ovarian cystadenocarcinomas. It is generally observed that ovarian cancer tends to remain intraabdominal even in advanced cases and that dissemination is usually by invasion of adjacent viscera, diffuse intraperitoneal implantation, and metastatic involvement of aortic and pelvic lymph nodes. Metastasizes to the uterine cervix, vagina, or vulva in ovarian cancer is rare. The reverse i.e. ovarian metastasis from cervical tumor is rather more common. Published literature suggest that, patients with cervical metastases had associated malignant ascites, retroperitoneal lymph node involvement, and significant peritoneal carcinomatosis. Cervical metastasis in ovarian malignancies always indicates the advanced stage of tumor and multi-organ involvement, indirectly stating poor prognosis. The median survival in cases of ovarian cancer metastasizing to cervix is 4.4 months. Authors report a case of bilateral ovarian serous cystadenocarcinoma metastasising to posterior lip of cervix resulted in poor prognosis and proved fatal for the patient with review of published literature.

Metrics

Metrics Loading ...

References

Lemoine NR, Hall PA. Epithelial tumors metastatic to the uterine cervix, A study of 33 cases and review of the literature. Cancer 1986;57:2002-5.

Mulvany NJ, Nirenberg A, Oster AG. Non-primary cervical adenocarcinomas. Pathol. 1996;28:293-7.

Mc Cluggage WG, Hurrell DP, Kennedy K. Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol. 2010;34:735-41.

Malpica A, Deavers MT. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary. Int J Gynecol Pathol. 2011;30:613-9.

Bogliolo S, Morotti M, Valenzano Menada M, Fulcheri E, Musizzano Y, Casabona F. Breast cancer with synchronous massive metastasis in the uterine cervix: a case report and review of the literature. Arch Gynecol Obstet. 2010;281:769-73.

Green AE, Biscotti C, Michener C, Belinson J. Isolated cervical metastasis of breast cancer: a case report and review of the literature. Gynecol Oncol. 2004;95 267-9.

Kai K, Takai N, Nasu K, Kira N, Ishii T, Kashima K, et al. Metastatic uterine cervical cancer originating in the lung: a case report. Gynecol Obstet Invest. 2009;68:269-71.

Guidozzi F, Sonnendecker EW, Wright C. Ovarian cancer with metastatic deposits in the cervix, vagina, or vulva preceding cytoreductive surgery. Gynecol Oncol. 1993;49(2):225-8.

Zannoni GF, Vellone VG, Petrillo M. Secondary malignancies of the uterine cervix: a potential diagnostic pitfall. Virchows Arch. 2013;463(1):23-9.

Kawamoto S, Urban BA, Fishman EK. CT of epithelial ovarian tumors. Radiographics. 1999;19:S85-102.

Gourtsoyiannis N. Clinical MRI of the Abdomen, Why, How, When. Springer Verlag. 2011;ISBN:3540856889.

Gupta G, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679-95.

Pérez-Montiel D, Serrano-Olvera A. Adenocarcinoma metastatic to the uterine cevix; a case series. J Obstet Gynaecol Res. 2012;38(3):541-9.

Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16 (ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle. 2011;10:2497-503.

Monk BJ, Dalton H, Farley JH. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol. 2013;86:161-75.

Le T, Hopkins L, Faught W. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol. 2007;105:712-5.

Mazzeo F, Berliere M, Kerger J. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol. 2003;90:163-9.